 This is an open-label, randomized clinical study with two stages to assess the maximum tolerated dose MTD, efficacy, and safety of selinexor, lenalidomide, and dexamethasone SLd in patients with relapsedrefractory RR multiple myeloma MM. The stages are dose escalation Phase 1 and expansion Phase 2. 